Results 211 to 220 of about 53,202 (260)

GLP-1RA Exposure and Nonarteritic Anterior Ischemic Optic Neuropathy Prevalence by Diabetes Status.

JAMA Ophthalmol
Nagdeve P, Griffin R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients

Current Hypertension Reviews, 2021
Background:Diabetes is a chronic disease with high complexity that demands strategic medical care with a multifactorial risk-reduction approach. Over the past decade, the treatment of type 2 diabetes mellitus (T2DM) has entirely changed. One of the paradigm changes has been the arrival of new drugs that reduce cardiovascular risk beyond the reduction ...
Aschner Pablo, Blanc Evelyn, Folino Claudia, Morosán A. Yanina   +3 more
openaire   +2 more sources

The GLP-1RAs: From Evolution to Revolution

The Singapore Family Physician, 2022
Research on incretin hormones has advanced considerably over the past few decades. Although the initial molecule – glucose-dependent insulinotropic polypeptide – failed to stimulate insulin secretion in patients with type 2 diabetes, it led to the discovery of glucagon-like peptide 1 (GLP-1). As GLP-1 impacts on various tissues and cells throughout the
openaire   +1 more source

Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity [PDF]

Diabetes Therapy
Introduction People with type 2 diabetes are at heightened risk for severe outcomes related to COVID-19 infection, including hospitalization, intensive care unit admission, and mortality.
Melissa Haendel, Hemalkumar B Mehta
exaly   +2 more sources

GLP-1RA based therapies in the young and old

Current Opinion in Endocrinology, Diabetes & Obesity
Purpose of review Obesity is recognized as a “gateway” chronic, progressive disease of dysfunctional adipocytes. Glucagon-like peptide-1 receptor agonist-based therapies (GLP1BTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without glucose-dependent insulinotropic polypeptide (GIP), have demonstrated ...
Georgia, Rigas, Shirley, Alexander, Cilla J, Haywood   +2 more
openaire   +2 more sources

Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA

Current Diabetes Reports, 2018
In addition to their effects on glycemic control, two specific classes of relatively new anti-diabetic drugs, namely the sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have demonstrated reduced rates of major adverse cardiovascular events (MACE) in subjects with type 2 diabetes (T2D) at high ...
Mansoor Husain
exaly   +3 more sources

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes [PDF]

Frontiers in Cardiovascular Medicine
PurposeSodium glucose co-transporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardioprotective effects in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD).
Ildiko Lingvay, Daniel F. Heitjan, Mujeeb A Basit   +2 more
exaly   +2 more sources

Semaglutide 2.4 Mg: The Latest GLP-1RA Approved for Obesity

Journal of Investigative Medicine, 2022
Ricardo Villela, Ricardo Correa
openaire   +2 more sources